9-September-2002 Pharmaceutical company Novogen (NRT) announced today that its NV- 04 cardio-vascular drug program has demonstrated “outstanding” characteristics in its first human clinical trial.
The objective of the trial was to determine the effects of NV-04 on widening of blood vessels, called dilation which enhances blood flow and can reduce blood pressure.
According to Dr Jaye Chin-Dusting, head of the Baker Institute Vascular Pharmacology Laboratory, who conducted the study at the Alfred Hospital, in Melbourne, the trial results have demonstrated outstanding potency of the drug and reproducibility in arterial dilation by enhancing the biochemical activities within the blood vessel wall.
Novogen's research director, professor Alan Husband, said the trial result represented a major milestone in the Novogen cardio-vascular drug program.
“We have demonstrated that the drug produces effects which are expected to be clinically relevant in improving cardiovascular function,” professor Husband said.
The NV04 drug program has already demonstrated significant benefits in animal studies, by effectively blocking the development of the types of lesions that are associated with the common forms of heart disease in humans.
At 1048 AEST Novogen shares were 10c higher to $1.95
NRT Price at posting:
0.0¢ Sentiment: None Disclosure: Held
